These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Severe hepatotoxicity in a patient on bosentan upon addition of methotrexate: reversible with resumption of methotrexate without bosentan. Dwyer N; Jones G; Kilpatrick D J Clin Rheumatol; 2009 Mar; 15(2):88-9. PubMed ID: 19265355 [No Abstract] [Full Text] [Related]
5. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. Eriksson C; Gustavsson A; Kronvall T; Tysk C J Gastrointestin Liver Dis; 2011 Mar; 20(1):77-80. PubMed ID: 21451802 [TBL] [Abstract][Full Text] [Related]
6. Bosentan for pulmonary hypertension. Dietrich CG; Geier A; Lammert F N Engl J Med; 2002 Jul; 347(4):292-4; author reply 292-4. PubMed ID: 12141332 [No Abstract] [Full Text] [Related]
7. CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers. Markert C; Burhenne J; Weiss J; Mikus G; Haefeli WE Clin Pharmacol Ther; 2014 Mar; 95(3):250-1. PubMed ID: 24048276 [No Abstract] [Full Text] [Related]
8. CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity. Roustit M; Fonrose X; Montani D; Girerd B; Stanke-Labesque F; Gonnet N; Humbert M; Cracowski JL Clin Pharmacol Ther; 2014 Jun; 95(6):583-5. PubMed ID: 24842639 [TBL] [Abstract][Full Text] [Related]
9. Response to "CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers". Markova SM; Schwartz JB; Kroetz DL Clin Pharmacol Ther; 2014 Mar; 95(3):252. PubMed ID: 24346422 [No Abstract] [Full Text] [Related]
10. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists]. Hoeper MM Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593 [TBL] [Abstract][Full Text] [Related]
11. The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension. Corris PA; Langleben D Eur Respir J; 2010 Feb; 35(2):460-1; author reply 461. PubMed ID: 20123858 [No Abstract] [Full Text] [Related]
13. Drug eruption due to bosentan in a patient with systemic sclerosis. Nagai Y; Yamanaka M; Nishimura S; Nakano A; Hasegawa A; Ishikawa O Mod Rheumatol; 2006; 16(3):188-90. PubMed ID: 16767560 [TBL] [Abstract][Full Text] [Related]
14. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension]. Montani D; Humbert M Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056 [No Abstract] [Full Text] [Related]
15. [Bosentan: a considerable increase in the survival of patients with pulmonary hypertension associated with systemic rheumatic diseases]. Volkov AV; Iudkina NN; Nikolaeva EV; Kurmukov IA; Glukhova SI; Nasonov EL Ter Arkh; 2014; 86(5):32-9. PubMed ID: 25026800 [TBL] [Abstract][Full Text] [Related]
16. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan. Don GW; Joseph F; Celermajer DS; Corte TJ Intern Med J; 2012 Dec; 42(12):1351-4. PubMed ID: 23253000 [TBL] [Abstract][Full Text] [Related]
17. Hidden hazards of Bosentan therapy in pulmonary hypertension. Sethi S; Sethi R; Wareham C Ann Card Anaesth; 2008; 11(2):138; author reply 138-9. PubMed ID: 18603762 [No Abstract] [Full Text] [Related]
18. Liver impairment after concomitant administration of bosentan and clarithromycin in systemic sclerosis. Caramaschi P; Mahamid H; Bambara LM; Biasi D Joint Bone Spine; 2010 Jan; 77(1):81-2. PubMed ID: 20022782 [No Abstract] [Full Text] [Related]
19. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. Ben-Yehuda O; Pizzuti D; Brown A; Littman M; Gillies H; Henig N; Peschel T J Am Coll Cardiol; 2012 Jul; 60(1):80-1. PubMed ID: 22578922 [No Abstract] [Full Text] [Related]
20. Genetic susceptibility to hepatoxicity due to bosentan treatment in pulmonary hypertension. Seyfarth HJ; Favreau N; Tennert C; Ruffert C; Halank M; Wirtz H; Mössner J; Rosendahl J; Kovacs P; Wittenburg H Ann Hepatol; 2014; 13(6):803-9. PubMed ID: 25332267 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]